MUFG Americas’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

MUFG Americas’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-160	Closed	-$3K	–	974
2017 Q4	$3K	Buy	+160	New	+$2.38K	﹤0.01%	937

Other funds holding SGMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MUFG Americas's SGMO Position: Q1 2018 in Review

MUFG Americas sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2018, closing a stake of 160 shares — an estimated $3K sold.

MUFG Americas first reported a position in SGMO in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 208 funds tracked by Wall St. Rank hold SGMO as of Q1 2018.

MUFG Americas reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2018 after selling out during the quarter.
MUFG Americas sold 160 SANGAMO THERAPEUTICS INC shares in Q1 2018, an estimated $3K.
MUFG Americas first reported a position in SANGAMO THERAPEUTICS INC in Q4 2017 and held it in 1 quarter.
MUFG Americas's SANGAMO THERAPEUTICS INC position peaked at $3K in Q4 2017.
208 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2018.

Based on MUFG Americas's 13F filing for Q1 2018, filed 7 May 2018.